Skip to main content
. Author manuscript; available in PMC: 2022 Oct 4.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2019 Jul 11;46(13):2819–2830. doi: 10.1007/s00259-019-04394-5

Figure 6.

Figure 6

Example of how the synergistic triad of vulnerability may translate into the clinical phenotypes of AD. Investigations of protein accumulation and examination of the critical contribution of the connectome and cell feature such as metabolic demand or gene expression profiles may lead to the observed spatial pattern of neuronal dysfunction that in turn produces distinct clinical phenotype in AD. AD = Alzheimer’s Disease, bvAD = behavioral variant of AD, lvPPA = logopenic variant of primary progressive aphasia, PCA= Posterior Cortical Atrophy.